VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an investor update Zoom call at 1:30pm PDT (4:30pm EDT) on Monday…


Previous articleatai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Next articleClearmind Medicine Announces Pricing of US$2.25 Million Public Offering